盐酸硫利达嗪 - CAS:130-61-0 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	盐酸硫利达嗪一键复制产品信息
英文名称:	Thioridazine hydrochloride
别名:	甲硫达嗪盐酸盐 Sonapax hydrochloride;10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine hydrochloride
CAS No:	130-61-0	分子式:	C₂₁H₂₇ClN₂S₂	分子量:	407.04
CAS No:	130-61-0
分子式:	C₂₁H₂₇ClN₂S₂
分子量:	407.04
MDL:	MFCD00012655	EINEC:	204-992-8
EINEC:	204-992-8

安全技术说明书(PDF) MSDS(PDF) 点击下载产品说明书(PDF)

T10810 盐酸硫利达嗪 ≥98% (普西唐-psaitong)

相关产品

包装规格：

25g in glass bottle

溶解性：

溶于DMSO（≥45mg/mL 超声）

产品描述：

基本信息

产品编号：	T10810
产品名称：	Thioridazine hydrochloride
CAS:	130-61-0	储存条件	粉末	-20℃	四年

分子式：	C21H27ClN2S2		溶于液体	-80℃	6个月
分子量	407.04			-20℃	1个月
化学名：	10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine hydrochloride
Solubility (25°C)：
体外:	DMSO	≥ 45 mg/mL (110.55mM)
	Ethanol
	Water	100 mg/mL (245.68mM; Need ultrasonic)
体内(现配现用):	请依序添加每种溶剂：10% DMSO→40% PEG300→5% Tween-80 →45% saline Solubility: ≥ 2.08 mg/mL (5.11mM); Clear solution
	此⽅案可获得 ≥ 2.08 mg/mL (5.11mM，饱和度未知) 的澄清溶液。以 1mL ⼯作液为例，取 100μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400μL PEG300 中，混合均匀；向上述体系中加⼊ 50 μ L Tween-80，混合均匀；然后继续加⼊ 450μL ⽣理盐⽔定容⾄ 1mL。
	请依序添加每种溶剂：10% DMSO→90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.11mM); Clear solution
	此⽅案可获得 ≥ 2.08 mg/mL (5.11mM，饱和度未知) 的澄清溶液。以 1mL ⼯作液为例，取 100μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中，混合均匀。
	请依序添加每种溶剂：10% DMSO→90% corn oil Solubility: ≥ 2.08 mg/mL (5.11mM); Clear solution
	此⽅案可获得 ≥ 2.08 mg/mL (5.11mM，饱和度未知) 的澄清溶液，此⽅案不适⽤于实验周期在半个⽉以上的实验。以 1mL ⼯作液为例，取 100μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900μL ⽟⽶油中，混合均匀。
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	2.4568mL	12.2838mL	24.5676mL
5mM	0.4914mL	2.4568mL	4.9135mL
10mM	0.2457mL	1.2284mL	2.4568mL

生物活性

产品描述	一种具有多巴胺 D4 受体选择性和 5-羟色胺拮抗作用的化合物。
靶点	Dopamine Receptor; Apoptosis; 5-HT Receptor; Autophagy; Bacterial
体外研究	Thioridazine (0.01-100μM; 48 h) reduces the cell viability of NCI-N87 and AGS cells in a concentration-dependent manner. Thioridazine (15μM; 24 h) reduces cell viability of the cervical (HeLa, Caski and C33A) and endometrial (HEC-1-A and KLE) cancer cells. Thioridazine (1-15μM; 24-48 h) induces gastric cancer cell death via the mitochondrial apoptosis pathway and mitochondrial pathway . Thioridazine (15μM; 24 h) modulates the regulation of cell cycle progression by interfering with the PI3K/Akt pathway and induces G1 cell cycle arrest in cervical and endometrial cancer cells . Thioridazine inhibits the growth of antibiotic-sensitive and multidrug-resistant strains of A. baumannii. Cell Proliferation Assay
	Cell Line:	NCI-N87 and AGS cells
	Concentration:	0.01, 0.1, 0.5, 1, 5, 10, 20, 50, 100μM
	Incubation Time:	48 hours
	Result:	Exhibited cytotoxicity in gastric cancer cells.
	Western Blot Analysis
	Cell Line:	NCI-N87 and AGS cells
	Concentration:	1, 5, 10, 15μM
	Incubation Time:	24, 48 hours
	Result:	Downregulated the precursors of caspase-9, caspase-8 and caspase-3.
体内研究	Thioridazine (25 mg/kg; i.p. every 3 days for 3 weeks) extends the survival of tumor-bearing mice and reduces the number of pluripotent embryonal carcinoma (EC) cells within tumors. Thioridazine (1.0-5.0 mg/kg; s.c.) reduces oral behavior and selectively blocks repetitive head bobbing.
	Animal Model:	Nude and Rag2KO mice were injected with iPS cells or NT2D1 cells
	Dosage:	25 mg/kg
	Administration:	I.p. every 3 days for 3 weeks
	Result:	Reduced the number of OCT4-expressing cells within malignant teratocarcinomas and extended the survival of tumor-bearing mice. With no effect on fertility.